Intravitreal Triamcinolone Acetonide for Diffue Diabetic Macular Edema: Phae 2 Trial Comparing 4 mg v 2 mg Original Reearch Article

Purpoe To propectively compare the efficacy and afety of 4 v 2 mg intravitreal triamcinolone acetonide (TA) injection for diabetic macular edema. Deign Interventional cae erie. Method patient: Thirty-two patient with diabetic macular edema unreponive to laer photocoagulation. intervention: Patient were randomly aigned to receive 4 or 2 mg intravitreal TA in one eye (16 patient in each group). main outcome meaure: The main outcome wa central macular thickne (CMT) meaured by optical coherence tomography (OCT) at four, 12, and 24 week. econdary outcome were gain in Early Treatment Diabetic Retinopathy tudy (ETDR) core, intraocular preure (IOP), cataract progreion, and duration of effect. Reult Before injection, mean (± D) CMT wa 564.5 ± 119 μm and 522.9 ± 148.5 μm in the 4- and 2-mg group, repectively. At four, 12, and 24 week after injection, it wa 275.0 ± 79.8, 271.4 ± 128.7, and 448.7 ± 146.4 μm, repectively, in the 4-mg group, and 267.3 ± 82.4, 289.8 ± 111.4, and 394.7 ± 178.9 μm, repectively, in the 2-mg group. At no time wa the difference in CMT between both group tatitically ignificant (P> 0.3). The between-group difference in the gain in the ETDR core and in IOP were not tatitically ignificant either. Diabetic macular edema recurred after a median period of 20 week v 16 week in the 4- and 2-mg group, repectively (P = 0.11). Concluion In the hort term, intravitreal injection of 4 or 2 mg TA doe not have different effect on CMT, viual acuity, or IOP.